Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting

ConclusionBreast cancer patients treated with trastuzumab in adjuvant setting seem to benefit from influenza vaccination in terms of immunogenicity without increasing the risk for adverse events. The current data support the recommendation to offer influenza vaccination in breast cancer patients treated with this type of targeted therapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research